Our Approach
At hVIVO, we play an important role in improving global health by supporting the clinical development of medicinal products. As a growing organisation, we recognise the importance of continually improving our governance and prioritising social and environmental values in all our work.
We are committed to operating as a responsible business; and as part of this commitment, we are working hard to continuously improve our environmental, social and governance protocols and policies. hVIVO has established a cross business working group, called the ESG Group, which focuses on identifying risks and opportunities related to climate change and other social and governance topics. The ESG Group is led by our CEO, Yamin ‘Mo’ Khan, and includes cross-company representatives, ensuring a well-rounded and integrated approach to ESG matters, with support from CBRE’s sustainability team. The ESG Group reports directly to the Audit and Risk Committee which is responsible for overseeing the Company’s ESG reporting and providing recommendations to the Board for final review and endorsement.
Advancing Health & Research
At hVIVO, we are aware of our pivotal role in facilitating our clients' endeavours to expedite the development of vital medicines through our comprehensive drug development consulting and clinical trial services. This commitment to social responsibility aligns with our vision of transforming global healthcare by revolutionising the drug development process through scientific ingenuity.
Commitment to our staff
Our team is the key to our success. At hVIVO, we foster a collaborative, inclusive, and supportive workplace where employee well-being, equality, and professional growth are our priorities. Through flexible working, training, and ESG-driven initiatives, we empower our people to thrive and succeed together.
Commitment to participants & patients
Social & community investment
Operating sustainably
Commitment to ethical & compliant business practices
Yamin 'Mo' Khan
CEO & Head of the ESG Group
"hVIVO is at the forefront of scientific innovation, but our success is defined by more than just financial success. It is measured by our ability to operate responsibly, ethically, and sustainably while driving meaningful change in global healthcare. I would like to sincerely thank our employees, trial participants, and partners for their dedication to scientific research. Together, we can deliver on our vision to transform global healthcare by revolutionising the drug development through scientific ingenuity.”
